HUE032132T2 - Kalcitonin génnel kapcsolatos peptid receptor - Google Patents

Kalcitonin génnel kapcsolatos peptid receptor Download PDF

Info

Publication number
HUE032132T2
HUE032132T2 HUE03736721A HUE03736721A HUE032132T2 HU E032132 T2 HUE032132 T2 HU E032132T2 HU E03736721 A HUE03736721 A HU E03736721A HU E03736721 A HUE03736721 A HU E03736721A HU E032132 T2 HUE032132 T2 HU E032132T2
Authority
HU
Hungary
Prior art keywords
oxo
dihydro
mmol
piperidine
mhz
Prior art date
Application number
HUE03736721A
Other languages
English (en)
Inventor
Prasad V Chaturvedula
Ling Chen
Rita Civiello
Charles Mark Conway
Andrew P Degnan
Gene M Dubowchik
Xiaojun Han
George N Karageorge
Guanglin Luo
John E Macor
Graham Poindexter
Shikha Vig
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE032132T2 publication Critical patent/HUE032132T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2807—Headache; Migraine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)

Claims (5)

  1. Szabadak« í, Kipkl szPmi (I) vegyük!:
    0) 1 ^|^;^ö#:grf^^íékeíU!öfpi^gaáliáS:'8ö|a ás: ; aPlvpa api:: Ψ -N-RS}{K: > vagy OR4: R4 H, C^aüdl C^b&amp;knlUi vagy {C „»IMkmfe(R'r R' < < >\U mI kn '«'«a« »i'ulKhl '<λμΚ>' ' " Lvi' x a "a '! ÍJ oî uí 10 pap, dioxokPl tussol, pinohl, pirsviihvlk pitPlMPk i-«kP»:î5^· ot>tö«>ixmh tmulazolsdmsl. puazoHi, püasoHmk pPiPIdlsük «.xazolsh Pixasudlk mzokk szsssus/aRsh ox»v?P:oh;: Pdi&amp;zoEi ïïîaïoRi. pkaml, pMdsl pidmlától:· Pxisői. ,pii$xÄk''MaÄ| •pitad'kimii ««»ΓοΙμκϊ, PtnorfePo vagy dlbxopdi ; év R* opek-skhom srobsgoukkva vau « kPeíPPud I vagy ?. ugyanaz«, ό vagy rvaonO<-:«; 15 sizyPzüiuea&amp;ieK amely ki van válásivá a kóvakedpvnl állá çsnpon.hô; halo. dare>. < sPtPs, t. i dsabtdklk Cx.oüPxk ΡΡχϊ, amin«. (. s.>dkba!hk h': pdbbtnsnsv C i.íPsPlamüu«, u. ; ptbstbuuieut«. fend ««: PíPI: as R4 «pcfendbns tan-aPc;.··· 1 v&amp;gy karba««·, ahol u karbasíl szPak^lR- <* kovvihtv.b gybossefiszefenek tasys: E'*; '0 R: 0 S' :!ï:.x.k:',;>ik fugu'Vki'·«' I \ okol Ív k« van s<sias, « a a b-· «fk-vz-oklv! dió «soponbb Ü, k ...bksi Ο; db««.. V bkod · k ..s,kd-'í..,í««'\ «>'-,«íi sd,, < - ««savak«, \ml «.bid·««. «οsin,·,««·, tctPxidroiuruníí, brand, dsovoksrül, tfeib, ieiranuhotussuk paroli!, phrdbik pisrotusunh lundas««;, iniukvdub -mtd,-·.. I «> tik p« vol ; '««adod pun .«bd «b osa old, iznxiUdu. ί az'hl \'tu*.-'«b idPutgóliL dPb/sdii, sisaddik ppglli piilik pRhbdbíL pssppR rppi^ÉA:: ás; pipasazirok tnorfobu·. «omyrfoîiaoep dioxolaüiU ea ' ' E >o \ 'gvk ' \i i i| vn , V^etk a's u ss! i '< ' s'.vsk O' I ' « ^ V 'hsotiï?'V -bdodvo »yv-K ««;,« r ,«, anr« k ·, .« sb.s í. . a koU'ikc.'Obxb db- -,¾ γ.·«"«', halo, ton l \d S · >k s kJ í ,!,k'\ h ii, \ aiixx,0í vl -add, <' ab , «'«,«, r b.bk-n«;v >Λ : Pkd>, aoeaks üsd es K-ar-L 3Ö k ,'s R' w · «'hsán ·,* p,o, jkxa« ia!í.'ln..'f I war ' kPvm ' ohei ^ k,iHv- « vr'Vioxva Is «•''u'îLî :s,í\ V'g! ; ,o',-\v iaftidov,. ,i ,· b. ',sa:k,'íá, K cs- Rk ahol Iá iípióíSáilhiiháa:: Sigvsilarih! el uu; valaszi va a íuirogésnöh -oíidyii'íy .l#:iit#ihïî!^ÂS:' va.o, ahíil Lr liiggoikisal Ci.salkikS'i ''agy Cj.-,aikrk<lk.<>; vagy ÀÉ X ptelt ymkteÄ imiteadmif, :¾¾¾¾¾¾¾¾ 1¾¾¾¾¾¾ :|>iiiwlldbilli öteftes! teseqnek ptertem:. p;pmds«il. moHbífeo vagy Skissorfo^so; îï"ä λ "íMwwlí-ais ; tes«i«uáhs s U>u'*U\-ïKe5 5 «tel 's stexclate y ,„s:kx5 v «aitejai, <"; pnhlaxmnxp Cs.^is^ikkiniiBo, 5..;~^texk CXtektesikii, 5nte, aíteáteL Rn-asig iS tkÄ, |s|rkoÄ ;|?tíöSkfeil,: ptoU<{«jar«{|;: tekteofíi itete&amp;oimÖi ykdateÉátel sydSäpiytföy^: lÜIHlife pteiÄO* '$fe«iiaKáfeík Síxspnii: dte«|teik pÄt telteitek-yhsdrohdteteíteoiote, ρ;ρ<·;*?»«! sapote«il, ms«Rteo. ,jtee«zotesjiï|s. temtoi&amp;wßl: v»^· koïterlbteo; éx «ho? X <fe V W >p*. x^xaU. n x;Äs;\ä < *c\ 'tel ί -N.lv x! '·η s , NH* *0*^Η··; WxkiW’Hx.^H- 4 il X A Sïsvil X d μ M 1 <' H k ' i x o^xsoteteap éi. fügstektei »«.tshvittetea \m a k$'«ifce?ted: 1 -flgy 2 u^vanaxoa ν*«γ MitebikíÓ s^b^ituensscl amefe kl \*n vâfevîxa a kôu«k«*?ôkhol allô «sop«n[|sèi; c* teksl, »nûmv Γ. 3ï|iâsïimi>, 3.«îs dlíkí5>iS3pfîiï>tis.:ΐaïksi, {G-ä,^ 1ks|>*.1 <1 IteXIl tetei?;, !.$ $4% ¥ ôpskmâlisâsî ks ifeggyieskll t&amp;mimm $ w$$ £íte*>öoi.% «tel. -¾ itefetete à- tetemlkf«s«k tägt'S; s kowikçjte X <fe V îtetn xp tegy te 3C sxaba.-teteiva va» a következőd; V<: tM te X «s Y aai)v% megxfekittA 7- wîi&amp;ww- X la Y ||tepâteâô: ^testete sp Äiteteiti és spteeskiism: 20 gs|; q m atel Q' iS'pRke* stel S' C;.ailkilcß'•.S;> (Λ'.aikd-tev! í-n * 5 25 U ni; xsgy NH: R* R* v*gY R* ahol B>3 (si a tefeivüktea atsdyaek van koß<· tessonafc gsxidsx a- · «tea a gyihúl·.. mindegyikében. a 30 teteocikias tariasBW. 1-5 sxgytegtek vste XiSidMte htícrasso-nos. síxísív ki \::Sn vdsssiva a fejfedőkből álló esapotíMk Ο. N és tM ·Ά·Μί^Μηη opaînaiisâ» fete Iß» t à karboml steaiifüjjîis ;x ftek'teilt sviimk taps; stel; Ri·* «pxmsslssiiix szute^fefei«? '·*« « k<ne!fext.(Vvsi: 1Y «gva«a;u>',5 vagy kaltelktex .8JMtetit«ei«s!ek aasily kl var- issh^'i'a a teunketetete all·;; cvsporite; teís:p,k lesni, -s í-kesill, -(>€.. 55 tekiysxkßli. -Γ. xalkikaRX H>kite>l, csana »iß«««'' *«»' 1:350 k spïksi. k : B^>:So :-n-tr;-hal>\kkii, 5 ; Sfíasxote hí hvsteiikte^ u alktn .'-«s>s dl' v-teR' t x.C^ R t'<\^*}« \(jn . Vä'kss«'hK '- \iR kssAsk ' X >1 \ ''K>F 'tete\j « vr^*Y SO.-teK/'i. :'x SO R 5 . 1:- H vagy ; ...sikk: RΛ R\ vo '\>'ï SH-m-O-ï'ÎU ϊάκόΙΌ AdornS-s,, ,.ι^ηίΙ-'ϋ-ίΑΜ-'-ΐί, MU-mnxmiUhotóUrSxmst}' ! H-tómű-3-tó \ H-smia/rd· A-À \ xns;:MilAtidmmO tóSxesVíűSsiíűí· Mk SitiiaxAbs-um- vil, ktîxo-iiA v3p> mf>kir«>l:X'.î. op-xxAhvaa a '^avasban ι«λ»<»·» «**- ViW owateíibáiyfc. 5 A&amp;n Γ»κ·γ, klót ' agv bíóas ai-xAmtótó vág* sUga/v vagy ne·« elágaz» «[feil «.'«oportokkaKC*.* tűÉikíáUA sextanok, fetóitókij us^H.>rM. ajkkal alkotó fenik SVmitótóKi. miliMtaeiik idSuKkarhrniiisSkiS ksi-botótóksk tókosiksilx-nik kath-sxi. üiaikiknt»8w*!kih xliaikiSxmxx'a&amp;oM* iifesk rí«»s. ammo, :ac^iükdibos· pmp mmiamSxk teistók &amp;Â?HëÂsk; Bsásö ítosSIkmm», saetóíw^^festó IdSosfeilxssii,. tóksteimeakarhntui, duiSKflamistokari'AmL tóíűmaií. o<aoo. tctrezoUL fenik píítdtnil. ·8&amp;, 11 !:|í'{Ú«-'{wiík««í, tnä&amp;w*Kt»ii}0' mftucwtcuNrutlUul· vágj· trifiuonn^iK>uifowl írattok; tóiéi á sx«bví:n:uexxBk Ishcuxtó xigya«asak vagy kùidsxSsÔaôk és a k'«S cmiacií Kxík>ű. IxAvxoÜasBŰKs-· Is KssmilsiKtemass asopoítok késinek yssksA pósSólagos;«; ssűS»mnstóva s feüil iÁtóKss il!.Ks\ idik- vagy brűxss ;αοααϊ·α1, vagy· atkil. ?;xSSxaíx-x:ís1; amkxs vagy scdxSxmsv#*· ősmxirrsai; » O; 5 5 SUR mtós. a íugggífósHö, | Kgy tó: tó hévig hogy h* a; tó-s η 0 i5kk<=r Λ îx-ax X ha aí akk<·} a sxmx tó '*gy IS kis a 2, xxkksx sx nem 2: 1 KOI vagy €: Sí Ovsgyl: &amp;s p S, akkor CS. } és SS egyik! a MHsAgű; aíkmtó; Λ' vágy A!' A3 kí'íxnéí X* ABX. sltív »w vtxA \<x kO h <> Ό s ov >ιρ χ ’ \-^¾ ; „^«sk IS miéSogtókoSóm s h^srocíkíus S&amp;ítalma? f-4 ugrana«»* vagy kűxSxixkitó Sx'x-ro&amp;ionsiX ηηκίν kx vau \aii' tXA XXAAttó s. \ÍX‘ Ι'Λ '\ O ' 1 \ A\ \ A\ «SioSosítóissiA iâïxsSAïsis 'l vsgy k ksSmsilg tóm! iaíkató&amp;sus! sKxsimmss: ss tóitómstóí temEhs hsgtó; Stó ::|·4 :tógS SxsSkíysMks, anstóy iigitsSlMig j~3 Kigasxomctó ax-tóy ki vsa válásává a ÍS5 OvX-V'aXÍhV! ,>JV -V! G is és 3; és ^&amp;Äta:t^h»M4si:karhxmii:% atótó a kaTSximiksgiixsSoxís a Ä^ftl Kihimbkim ssgtó; Ahol .Af :|S A'' opCKsdíijSA v-^gí-xlgig^vA vass s koxviksikiws: (k.lsSkil k'j..jaSk<>'<·. Cs. .Ado 'k A V i S.Í S vil í) íSvsv ti i! vi i t- i> Hl>SiA {'»KSd.Xtí i íK )A S i V X'< ^ asi Jx xSî N s e iS X a >S>s Ai Ai »I» i í'.Sv>í>> p \<v i iS 31 xsgv iisAsiV A, V;i,-v p 0 Ágy, S:i>gy G és i AnnsSAgyik A· hsxv kmxmoiódik. Bkk=x Λ C,:fc CS: I K x\ együk ΚΑϋνχ:ο;χϋ\;ί\ igjSnxs svxd'xzőn ;SkxX shd a ;·:χ·;Κ·">Ό' gyűrűi Asi-AiAsSssÁk Λ-; xk tóvtó G. i gs Λ egsűű GJA’ vagy GJaí: ühöí *'*Λ' 's' \ ív;'„ A ϊ·'' O kV' ΛΑ agy A; V;tsXe.; hsxxy A* Ä;il#)iÄ#ii hcRr;>c:skhS> -.'s A* «ata î. <V «svakba fblsbva. k:>gy ha Q Q' alcKsa IV R;a vsgy R' H\p (I<v u,ii'< \ » KanU.^Î ä'Ka'55«. i î V' â; '- *iX»ï» X s si aî 's's oî il'! v> kKt \ R 5, A* .kVgAyyam 4«β'·'Μ»^Ι^. O Q’- KS sfP* ês | G agy.
  2. V>gy G. J ôs Λ együk a A>U' kçj'OÏ Äik>>äKs sdA '
  3. 3.4 -:)2:50:0- ΓΗ- k 4κ4ΐη· )--o;s· 6-d
    I^--D^íulK-hea^oldin J]0Xi:2Í·;-)·<.·&amp;-6--·à Π 3iáköMdro* !!!'k5RSí®!k^2-o«-&amp;--4 τ Μ\Κ14 - ).4--dihid:0-- ; H4:lna/X;SfP ·.) -<;>v 4 -4
    vsgj- 4|I^Bïîr»>!îS
    ahol p' |·Ι; C'späksii F * Pl Br vagy PMk P:, VPgydfes. rund y h pia PïlPdyà .3 Ipvetkvpkba! gild psöiprifeák ^ V '.iK- I '· AÍní'g 'B \Si^g η ' ' ^ pv\na v 5 k«d \ vy I ' I" i^vdiP s 0 5 brd:»· IH KRÎa/olP-ihaabl·· Il nx<>· PB aÏind: 4--(3-040Ί d-;xddS?κ^k&amp;¾l¾pe^ îàs-d ·43}>ρίρΓΐ<ΙίΡΐ^ kâippI|pvBBôp>· ί ΟΡ-ρχρ -pp hcn:·-:··;x«K44v4bï:cb!)· 3--(4--p» idns- 4 -4--pgX:î'«?iB- I 41 BMI]·an su;. 4-vp-Oxi>yÍ:4-di!ddysn;2ll-Pías!gölig:d^í|Bi5Ípsíidla^kPgfl>i>sllsgvr2»ax0d:“dPí>Svnd3dílbslrc;:· fees^saxís^^lmsdl^-píissíá'd^ldl-^l^síusái. I ¢) 4-{2-0.v> ï B-pilgdltP H -kin.i« :1ίη· 4 4t)-;;:»p<-u4b>- I -kàîBgOÎpv(34440 g ΐύ-ρίρνταχί-ν I - il B3 400- \ -(Paso-2,3 pilBâPbeîIPpÂpBPïl 44! II Bd il 1 -a-rnd : 443'ö:sö'Í4Pp54ííx4í44kIsaxölIS'3-íl)-ybpéBdíS>iPgí%sysygaxf3¥|'M:PIpÍ|mrktiPá4l'-4!‘Pl:44'· apliSy2'-öxSí'-33PlblílíPPs-sixxíX8Xxd.'d-slaáedI)-d>ö^iV8íil]-a;mkb dBS^ÖMl'lPdllidnadHPbPplípplllpspgBdbpI feSKaxíiSíylP-Ufaedllvpjxsxd-pixgldís-ídlPlIi-amM; ï-kaflxíAsBad I -{•dkIof--4-<-vo-:;.:'-d;lBd;i>. 1>îî six»k SKpl-P-limpí I!>' 2 - ö sip- 2 -piiserlcipi-1 11 - sí i I ) >ïîsïîiii: |0 4-^(3Ρρρ-:!Ρ-·ι1ΙΜ4Β^·214--0Ι&amp;»χί0ίί>Ρί'0;Βΐ:0ρΡίί1η·4Β3δΡίαχίΒα:νί1Ρί^ό0ίΡΡδ^ΐ4!;-344;:ΐ8^0}Ρ'- <>>;<' -2,3- 40'4lry--he;ïX<.a ar-d-n · d H'O j-aand; 4 ^i(2^t:4LKS5^ ! 1 '2'p4iö-2sSp3Pi|^?^ Bgögracggo 1-0-41)--1- dbncdlkarbn-xsd 1 - ï-blj-a&amp;d Ü ; •lx 2-Or*· 1,4 ·4;Κχ0χν2Η-ΚαΒίχηί;α-4-;ί)-ρηχ·:4ίίη- 04α0χ:χ1Βανί I--‘4 -rncgl· 2 *χ<θ!.3-*4·κ4·> 35: bv «:·*?.w>"d··! '6--lbn*dsb2-nx*-3 44-ρη'κύΒ-4 -d-plpararv* b4b<-n!j-;sa«d: 444PpQdB4bl0drodIf-:k0d2aî0ppd}40f4P4ï4-i'%4rb0d!sp^^ K:-ftr*xar<4-b4br*:d!p2-c*aP-d-p!rk:b:v4-b-pip<.-iny0;-'S41)-401] -aabíl; 4-(2--¢>x:Pid^:d¾bdm-3H^k&amp;daal0^3-i;340p¢Pdíöiî4kar!îΐJxils3vf2iflp30l|?SIXgri0igj^lb]I.-)ά{4--· e b 04 - ysxö-> 3 4-dlldiiyx-Nas:o5a:ái0-bxiBöetdl-iS^ axöN-g íü|-s mBb 30 4-·(2·Ομ5- !:--»--díhd.c<>- 21k-keax*bn 3-4ΐ-ρφοπ45ΐ-4 -knfhnrbxAdxb 1pVjbtfxpi'rkhxd- 1'··4··2·-νχ*· ! 4 2-νχν· 44 -dïhulro- Hl.b<-Bx;!indsX'4.-5-!p-:s:i-;r--apSI--:n-00: 4--(3-Οχη·1. -s-sbhidas·2Η·-κή*ι*>η·;·-.'-4;-pip;van«· i -Oxboxdvsx i5-j Lb|blpipcr;dn:0· 141- À p- xk4i-2-axo-24-40v4:Xv B24wx4niXki;-:4· >- 4nuPii)-3-(ïXi--<-aij--<i!s-xl 4-i ;ί··0κ>·4 4-d4:Klr>2B-ks5s?í3olsrs- ? -4kp>pcsvjm-i--k;:'4xcx4:-;-3y=;?4 S 41cip;p<:ruh=?4· =‘-4-4 ·Γ5?· kk;='-2-<:=xc- li 3 vlîhîih ·>· ^ ï? - îîî? ΐ i »; î îïs ida:»> |> 5 ^ ilmèti t ) > 2 ·ο?ί o -¾ tí? | - ίΐϊΐΐ ki ; 4^C:^O?i.0-ï. 1.4#r<ií1íí.d^r2M^M:«ssoHsi--3--ii^|>Í|5^rií<t'íiMÍ--;!k<íírl>oXí-l.-ss'yl3.íX ï ,^-^Ιίΐρίξ^^^ΐΐΐΐ'ΐί-ΐ’-ΐΙ-ί.Ι. -0- I ^“íliísií3írvV'3 í-í-^ící î3#â'<>Iï'iî^- 3---:tl)---i>ipër í’tí'm^:.'l :^|iâirfeô3S --:11^-- '$Rei:ík?:Hp«v3s3*á&amp;k!s^í.M>&amp;SjS&amp;tiíííd^^^ -•-=2-Q=í=>4 4 dihidrcí 2H'k;íSi!í:<ún^3-Íl}'>>;p<íS'ukív I b:ut>os>Hsn| kik 4:;fnpsjx:rkku;!·}'-à'Si -{λ.':· iíöxssíHv^öso^2j3^bsdför:)H^^fei^Kdr5^^í®(ü}';3".5iXíS“^ö!:)-'8msá·; J-Ocöso * s ! ί i tî" » 1 > μ n ' hK' \ t ’ :'i,4·.} $pipggi&amp;$$M *=4W ~ü- Skl4í~Sc4:pPí4*Sl'4^ 4- >(3íCk^k4''ási4áí^'-21I^MíKsas44S“3:4l4i>sp§rs4^kk-k<?í!5í5xÍss«p4tí44l4|4^en444l-r4kl47·' <.ΊϊΙ -3 · meTil'2-íjíUí- 2 ;3 '4jhKÍ>>>4!4k:í;s?mu4::K4-5· ί;!ηίΐ«Ιί·3·<5χο·<:!4|·::>!ϊ:κ;: 3¾ -4 7 ·- Kl feSâl -1 |: í > ií ί<ί=ί:^ΐϊϊ --3- H} - -2 -1 [ 4> (;3 ' <s kΐ>> 1,4 > <libidó 2 Μ - ki sias-k^ M4' 3“31;)^ pï p3 ^-káí bötí s11 - ;;î«s!ï«; •fsí->pí:>«'íuv ίζορ-χψ;! 4sS4pf; ^4?^Κ1όί^1Β·4β4^?4^541}<2>{[#^{2νΐ>χ^^4^5^:ΐ4^3ΐ:ί'^454?ο^·ΐ4ί4ΐ)*ρΐ|><'^4ξϊ}·^·-^;0Ηκίΐϊΐ0"· .ammof impc®pû isaler; 3- 47~bt.= l· ί Μ4pásPól-S- s: > · 3- ; |4-{4 í>s<- !;4'-4·3ίΐ'44)*Χί4443 - íi} pspvrriüps-! -k^m-ccdÍJ - s.®iSö : -propKCXcv !/>:>pyftpx ésSSer; 1'47-Mö4J'4íl'Jíi4sKí4:4-'iík2-1 [44'2^»sí*í4“áítóár^2H»kíí5'»5^á#^i^ndiö*!^sfe«»5l}·?: íöbííSó I -ps'epiöösíi V kírtí'-butsí éssísr: J-jÍ-JíSísir-í Mksí444p.k5*sí)'4'' 15442x44- 1 pí<yÍ!Í4í4-2H;4ispak!Íö:-3'Jlkpíp«íu4a· í =-ks4ÍK>b4S-> öx=4x<; -propisxjsav -cfv-kyii- =4.4cr; .Vi'M'kk -H- ixikí/os-sks! · k: · :kk(koxi>4/ixK;si;4x-4í l-kk;s?s?ís:in· k-s4-ps;>fryii:s· i îxîîîïos-îs ! sí rni η·. :·;í -pbsjjiPsíks v · csx - bus ií csíSp ; >··ί 'x-íiJor· í H-síídxíSi<4-5-îî>-4 · ;54 ik·i.4 ííihsüí';> 2ís-^=5^^01=^-3·i!> pííXí?idhï· 1 -küíίχ·ηϋí »t»jïs> = -ρχ-ρκίΐχχίΥ sikíöísés sí cxs-sívs : k-'i7 - Î..ÎSÎ · 1 SO í sissiíí^íá í -5 - i í )--7 - í [ s4 - í í >s i>-1:4 --iîï íxi díi ï- 213 - k íxs S:« v| sys ^ 3 - S î>-pi| S e tiï í S ft > ) -ká s 4? í>ís £Í j - isSSitäß«) 'prcîpiiîissîiv <4kk:kí??41 bxíSss; 3Ί7·Μ<;=4·;Β-χΐ;4;ΐ.··χ4-5·45ί-2-·-;i4 (2·χ>χο· 1 ,.4-d=issùro-7ίΗ-ki?5<:s?<3is: 2-iSi-pspcndcs-:==Β4ίχίΡ44 <nsn=Xf ; -prspnix-.-scv i -;x:=X;i-píiXí=x45sv4-S; csíp:;·; S'- = 7-400=- ί ί ί - i 5": i í=s= :-:<. 3 · 3 · ï í î · 2 ; :4-= Sb-s; xc-1.4--454 ;4ro--2H -k:/==sz;4=xi- Si 4} plpcaPyx l·kosfe-mlj sïsskx* I -|xs>äjs4s5ssc I : - sse il kpipxíísiíb fi-4-41 c-cxc? .
  4. 4. Λ À v?igv X i^napoot axaoaíí 'VgyüJín. aiK.à Q Q' V A ; . 1 A A vagy J ^dnypom sa-Hm* u-gyltet. ufcoJ Q Q*és Is NH ?>. \t \ igv'-jyjv«« s» *x«'f v»V'aa'}' * ^*·'5 ¥ - í v \> ' 's is CU· t sj.j\i ΐ abs X ^ λ (R t A \' j» V\ aï V ϊ m 'V. c V' '* U (. 4 k»i ' k' u V \ s'îA t> V i C;s. •cGdôalkà.
    9. Aï G iöGíivpmb »s«ï;>t; vegyikík ;-.hs.G V •NbR'HR' j é» ;V -.. K'' taiiüh-'avjk Rlggeűsadü V. «hol L* ks van vàGsSïîvs a kiHefeAîldkd aSlo cmî^mmîIxïI: H, V „VI. y > s i" ov!' 'u Jki'" s V AkxîA'S ;vai;„ ísdöíííasiük iaîrahkkoViamL Gy ans s. s J«v îxi î K'Ki'î], S A' OïtOÎJ'lt ^oohosrí (i \K* Iss* «»s * »'** <* ! ' R * ν' Í " SX s! \ Uk pi «'(MbVk pSia/eXdiXi' OVi'sh» A'WOid Sä s? Mlu SA>SXi(\'h* s»ssïdliVOÎii. !:ikäW\'!sä Sr.«Vs'hk pAäVk pináil ptnsmdmtl. piracinil. pipenduiil«. pjperimnik «wrfoßt», s;sa«*n*Hsx- ?.·« iSî^sokiiîU vagy r» és rs egyöu a nixoix í^d, amelybe* J^áoíódftak^if^efezfk^MÖIR··^ j;x>I X iiiskduxL pirrohsü, plrfoháinií. smkfciAíjmsl. smidaAdsstod, piraábimík p«-áA>mMm. VA"k'' >1-*.· ípiak bfs.x-'S'x p pe >lí«'b - K'ds^ ns> s í'('3Xív>f G>xtis!s síből X !Síubs.?!WsaH-a vaß « fmvclfcoaftvçl· V. ídad; % dsbSö>ä?Gk \ *.*3liçd.< -ιί!'·’“' '“' * ixkk'idkG. &amp;tdk aftciuHmh.. mmsUL pi'îolind. pktohdimiy iRskRÄWÄ mxbibïvMi .«id&amp;kv»·«'* mmlaAdidma. umdaAdidinomk ρ»$κΆΚ ^>?»2oh«d, prMPMÄ':##Ä psnüA p^tn^>ß>'· Gihkis^s^assdi^Bk'Sxl HpAidmsi GÄdiÄ heftinN^HG ä t^fîtor î ^ î v no k: Gs5 ahoi 3Ç··'# ¥ ^|5<sÎis;Î^iiL-M^tt:'<is^ï-s^ïîÂli; e^^t^èïssïs-ïmsssi-iés : ëgvsti cikií^íA κι.«·:. Ijy s spvϊ'Λs"'''·'s5 six"' 'Ç$.>sd-k 'bvd S X*R Ή »s'· • 5·· EP lifM R- es R-irtiäVsV'-A tu-X s-*»' V '- " t·. owS ό' * >R C;.,.iSRR R\'s k ,j ,χο - an .χη.γ. οη.Κ!«"Ή\ ' R"!s .s vv.'kevt EkYois V Slîss!::IX :pipexKÜí»? #gy íMí'MPkíS 'iîîo! X vJ,s "'< Pk \ -ϊΚ'Άϊ!\ί( s ! kkk '.a,", 's^'íK—k eoaho XvV Yv <M'. 'Vííi 's "O'vk·' Ο Y>ÔE Y” ''kk"" n's/; .sk' ? Ϊ Y S niY 4 ^ ^ * a s ^ iE>'' <*hv' K i' Λ M*v ikUOïCs U í » 'M ss ' a a '.¾. . .\.! 5 ík<. Akkk rV .mh ' 2v i' s iïlk .
    12. Ai I. 1^γ\φ<;η^ SYr-nrs \í:gv2i;<'·, ssEoi V -Afk' ;·.1·<'} os ahol: R R' '5 a Î'4'î'^ï Í '*'«*?. íí'Hkk ' V YN>ok\KXv Ci k 'viftk<.>c,ii ak. 'ï.sk X sfesi .;&amp; pjprsüSáil xagy smíRkteX; ark X s-ukeusRoE "- .Ci 3 k'c:v'ío'k Y kik V a«-'Ví?íW»«S í.. asikiUajMiiíH-rulPkl'. „ kk \ s. \ OT'i 'SS s'n!« va» ÍS' OtMJaMK . S'UOS s$<îï.> xkkjs.is Basses: iSíkí! . ••Il* \&amp; I. «»en*«* 4\-gy»k>t. cAk V Ni.R^’R'.î es atel R* ih V? e*yiia &amp; mtsowysei, c»na?lyheü kapcaö&amp;dask, s kdw’Hrcæft slkoy&amp;k. X. ab«? X piçfC'Îcilsiîîk ab«? X w}ljs»tituá?V8 sas-aköveík&amp;?<k*l: Y.kteí Y pi^'ndssul ;l:Sk Az i. »g«nyp*'ttt «kttuHí v«gySi>|k;;Xí|s'í| X' R") es $ho! R'· és ,R:i eyyëts a nstss-sgé-ineL amelybe* kapckoteôk a kövkketes aitekite: X. öhe? X ríiorklmo; alsói X \xub.s25saki!vs vsn s kteetketever Y, ah«? V Cs.Eíilok lő. .Az i u yon* \ V* 'ií'.vv4k' sv > X \{R ER ks síi·'* R: és R; együsi ss sssssogtes'.eK ssrsselyheí: kapó skóciak. a köv.'íkvEs .síkosuk \ estel X. Rtptedmsb estei \; st/ïibsfUsitâivîx '.aî'. a tes. viksvCS’-i. i A. alsói X R; ^ates EX As ? sgessypcsns ssæxsisis ve^yâte, atel V teiRScIYten akR R .·' R tfgvuRá «ïn^s'ie?. ais*\V> teywx.te sk o k nmtete sR. i-esk \ aboi X pipenchte; aboi X SKutealteàivs vssna kóvesks?e.dveS: V, Α>! X ai;>s<iî.assa. ^ «k? X . ^ OvioO Rf i.'- -ν>ί»"«' N N Έ-* î 'a*«'» skv.v- Os R ok.s A?· Az 3. spüXP°k «særlssss vagyiR:?k isi·»! R' R3' es R'" «;?ub^»t<uàb v^fy ÿxuhs?«buàla}btt ÄÄMaÄis^:. ÄÄM| ikixklíRsi eamskskísofkos^R, ipcIsxkeokisYlIk'iíssk IzokissoRjak, -á}Íi:klml^í^Í.»st3ljíSímílkksspRRAt ^Äroksns^shöonsk hklrokmox&amp;baomk ksR«\a?siu^ k'4i.'.'is«3i>'bl ii'uki. .'kl Oik'j' Is.si'to-akioiiOak h ko okessc a as d.},·' c> k ;c ; s ä. Eoo:osixsvisiväJ5'-<k 4sk<2iV' RegÄeotMic .kW$Êm?M$MùpMx E.'n«ss<<robl, a»isKb . ?xsn«>irk.<ob.li a'hidroha:woisoi'enoiinf hPRok’siiOisoi'eni'aii: hen.-iioeiili. aRisbnsbossaxsikiaisossIk hki{<i?x'si;s..sR!!sss«s(!)t, ba«Klxix.«i<md» Öi&amp;dro3«k>kmtk hídromdo-ooib hssMSL bxbkxiÄ Ssoxxloki, isxkdsdd, «»Wb ρΧΧΓ». '! : A'OlopîUÏSi'dsM'» ' 'g\ X'ÎXp0»k''P'»S»*..'\'k‘pî> X{»mi, kS -w Î itp«ypc*t ««mtii vegypfci» »dxd # u" va fi's vabmismsik Bf smkzsMfe^Mm ddedmixm:Amkhm<:ksnik hidoilteaxsmxiaxokadl fesomokbabÍMi> 4jáyi»^»Í»!í»JÍl? MdmfesîsÂ^feasï> ifcamisæÂ. àiyàr»i^mm|; hlfe^mÂ4feïKsài, 4|hs^s4sëbxoki:mM4, iddmtvtxxoikmsAsb], 4|ksdsdlPdbîP?0k SÄbsdöhmk iösblisíklb SadoibbS.: pi£Mh %k#siliÄ í s máj va abpgy m $. bxnjfsmbssife van Írva. |ft: A? ) mvnmà vcçyâiet» a&amp;>I l> O «s ns ex « tmsaâegytk 1 :34:: Ax 1. igàsyixmkvamnd vvgyidab afed: p I ; A; G» J éx Si «gybP a köv-xsago- aisopa: Λ; vagy AA 2S. ',v ' mmugoai >< mmn v»g\v»x »dxP a 'I«,’', a yp m V ~ i mm»k-sA m -vKv kx s^kd-x» akkoí·-A C-4* €x j éx A çgyüit apawskSeso* gyârù femSwA aikot, adói a ?«fttd>?<'t g>-mtií mxxtbmrxaxA A- S ès aboi Ci, J ès A çgyûtt G.iA' vagy GJ.Vk
    33. Ax S. Sgéavoxotï-íxestots vçgySSSo! aixd p 0 ágy. Smyy G sa ;f Äsrfgjjptk. &amp;-&amp;>x fcsp<. «tiodMk »tkkor A € A G. J ê:> A egyù-t spsxotakhrso». gyűrd s'eodsxm ab«*?, ahoi s renávm- gyS'ma Sanaknaxsaik A-tèx ahoi ö.Jbs: A együtt G.S.A'. 21 Λ S ηχ-χοο» ' \»» ' 5. ' »xs'N'i et, -ah«l p O bgy. bogy G es 1 mmdegytk A-Ssox kapeaobabk. akko? A C és G, J tA Λ egyyü vynodidume gyűrű rendvge-rt aSkd. ;4κ3 « rendszer gyűrűi sarsaimaxsák A-tèy ifepl. %:ßM Aegytii GJFA*, M Ai: i. igdftypotn szemül '»egyölet» »thoi p 0 ügy» itogy G es ? mindegyik fc#P^|§4ík> tkkor G. J è» A együx apxsocikisASos.gyúró reodszess. alkot, xlxd a rendszer gyéről igAdpiágzak Ad Ak theO G. s év- Λ «gyűli S-emmeskSuX askomak amely ki van vűlsszAa a köv«tkea.ókl5<á sHo esopvrtboS: mad&amp;ioliaxsHlk smSdaiRxHdiaosaS» tuSjiílroknKfHoosaS, dihSxSroixoGobiomkí, ddmirokinaeoimomS, dthidxAeKssöygSmejitk íkkSdfoíH;o;a>xa:íSí5Ík laikolxasitoxaxsolk iMSií4tGxmaOx&amp;aixs>ijík dkistkoSx-axiatKiaaoiiS» dShSds'O'SaexeitsaitaiotsjL. xijkjdfölxíííaSíííasaxL aknidttxbefsAkißbooKiis <iMds:dxmsxríiASiasöik: dllifebdölotkk Síatollstk pkgxoSssSk pttsaölidbsL pimdx-ü, |>i«'alsilxïil, xaSdaaxdiail smidaxsSMtJ«l> pSpvrxktnl. plperasdxtd éa mßdislsso; :akpl s sgagAxakASS Îspesôsâksasi: :satsbxxtkualvs van » ;fcpy$ife#yd§ Cm<Ä3» iCpiáSlíikl, Cgakaíoglkik PigŐP< iCi^tsifcSskgkd. lenSSi ItsälelssiSil;. ikeapil;. jsWÄp |éô;p!âî· pt?ÄMM.» diddagsdik ipdjdädiddsib: ípssdsyplIdmSb pdtodd> :P>.vs/'"Hïv:: píTaxobdtítik poxliS, pxltii:dätü. y ívva d mii, ptperaxiro! vagy o-orSidS-K). 35:, VggySlkHvAptete Ml vap^teiya a kôv«î.kexdkbiH add cvoponbóS: Cl)-:k-G2»Ä5s>iG -alp, ||4#0xeG: px»>pkavsav; '4» ». kb' "'£} * A ' "î.d.t k'bndMN ' 11' i P^e!, C I /iG i iïiiiïÂijI* 5 i 11¾¾¾ S il)y 2 -As -öG ! J iö 5^s Αΐί ; S.:>4-{2-Oxr>-2A-dduib<i-ixaxoxx«S«xeM-d)-päSAnd5.a- i-kasboxibavji-s M'jbp^endxtd-i -Ρ- Ι - U?AxkN ô-sbomfi} ' »i\o «tîS: o-r.id: < . î-4--d}-piperidmO-fc«rfcoxH^v{2--( !Ojbdapuidisü!-1'-il-! -· 5 ! «-indûïo!- V Utnetiis-2.<*0.«nH^sd. V ί'* V- 0^.-1 >. -Yb χ - ?H UttNX >m ' f\\ t N'V'iK\.o' I î H s ,|.,'' 1 * - H-ïïivîoi-? Om«iü}- O-m-uîÜHut-i; {· ,f-4 î λ-ΟχοΟ,4-<l?n^ís>-2M«kjiRáua}Hts-^ (!>pipendas- V-kaKkîxd&amp;svp -| ! .«**|ï»px{»crîUimi· l!-iM -OU -utdaMl· S-ilmtuI). ï^x*··- m\)..mnâ {"· Ή -\ .·' < îxo- 2, >.xhhuko- hff<>,i<;45\i(lM.<ii-dy}'pipeidiß-idMfeöOh&amp;v[:4yiH-!500-5.'sh5!ffiiij'2'0-: wbu: d-p^ex»«-. î - i] .wï<Hftii} - *»«&amp; ί-^5^-8-ίΟ-ΟΟΗ-^^4-ίΐ5ϊΐ«·αί-ί-'^^ι>Μ'·«'5»4: f~}-4-i ?.-Οχ<·.. .5 3 ài1l:diX·. -OiíV-.YíyO&amp;íOÍ 4 -îU- ^m..4,..%d^Â'Vp p UOsjdSzO-^-4}:mii}Oi i 4- s/obîsîü-pspmi p.i-. j .-I). 2-tno.cHîHaiidj 1·.·:,!-^- i 4-Oso-^j>(jjtódm-%fi}^c,}ö}íd&amp;xol· 5 -il ? A-dioxa-S-a»*· -Ç îïï-t^ÂÂoi-S-’sinietiO-SO'SO-vsii |-?ïïï.ïî<î (.•.î'^-5 M)xo- i ^4-djfedm-2W-kjaaa:o{hï-3'd)-p{pèrldjn-> -karho\dsa\i2 -{i .d-daísa-S-a/a-xptro|4.5)àec--Ό >h-ï -i} //-iadaxö!-5 -.dniebiK-b-oxsYuil ksa-íd. 1 ' ' -. 'U V i 'il; ' + «‘ 'va v 4 Ux* -Ois1 a {tt ' i iî-S-KSiksïtîb· asmnoppiopOnYav í^íít; JM "--Mekl·1H-miíaB<>l"5-ii ?-(.?:Jí~difeid:'íí"2'-<ixosp»<íi“{pipcndm-4,4'"(iHj-'M:»aKoK:H'íksjísií»3 ajîî.s >:ü) j - pr; ?p ;<sii«av ï;;<·' d feta r; ?··{?-Νίό^ί-ΙΗ'!«^^ο^54}}··ί-ί î J-«dL!dr^-d^.>xftsp{p^4lï^4^iy^^|^^ô^|Eî-4^î?jp|]|5dsàm-· : 1«arkïO?0|^ÎÂi iô>> fögjsönííí^ : 4¾ éí í | esgt-s^j: (·.;· s -J 47-Muil -11 Madm-a- 5-0)-2- i j 4 -(2 -vmv- i ,-î -<OïÜk- 2i i- kOa^On- kOHnpusMiv î · karO>ruH- (44--4- í ^ -0 s ïî-4 >1 <- dî bid «i - ίϊΉ - I ί ϊΐ - 0--I l> - î jshiísííU > -14fe4Sîdï» S il s s v| 3 -| î ^4 \| gses s ; -Ο I - rMmeüS- ? H-->«da^>l-?--jlr-iotíji)-2-o\o-i'iü]-&amp;a)td: 5 ü.1 M'v 1 î'Udxb 5 O.-SvXUAhtt ' > '-'-S|\\*iU' î 0' !'5.iiUU^ iä\ .' ν' ^ 1pppil)*2-oxv-2-piperi&amp;ö' i - Π -ctHj'&amp;mk!; ^ ^j Ií^hSíÍíiOí^s-S 1¾ - - 5 '¥ίϊ0:?5ίΐ*ΐ·ίÎÎî 4 - k(îxb<ÎsO - < IΪ ΐ íííst ö-fe äSsbisyiius ( -)2 - £'5' - meO-í (k-a;daaok:MlMadMKmà. ' *' mo 4 »h'xt f> '' >» 'Èm * *1' >'{,%. v λ Ux4<'Xx is - C '^ΜΜ4κφηψ^· ilî-.ioîsâ;-;: -(-l-amííl-pípei^öv i-îl>-^xx^«eÖ0*smíd( ibtïçuh-d'i'.'.o 2-p'i'.'4s4!!x- i · s! e»î y-ad. : -ä -5-îO <K-' i 4 diKsdîx- 2H XiSViAîhn-s-t»' ' s-^AtO'xd'-χΟ .'' ηίΌ-Uä nuoM-'' dmenh 2-ν*χο-00--ρίΐΌΐθ-4-'.Η·>ϊί'ΧΚϊ<'ίΐ·-ί-ΐ54 o«U ,«m>l, x - Y. '.\\ . ; i Λ '•{»»Iso 'U \«u"hn ' -5'pip-'TïJi-î l-ksrbmd'ï\ 3 ( ' *xset**---ifu'i'o\'s 4{'ïdi' ' - 'tp ' * ί 0>·-”.:^.!ί:{· {-H -i ?·Μ«Η-1 H-imSa*oî-5 üro«jtV 2-f M*fcpiper«ltoî Λλ\ O- owi ù ira-enesr-'b i>iii }V mp.voW{ - î > > k\ ' i Uvv sîtr ^ (Cvir'i ''v'' 1 ’ 1ïts V ' X'N" .Γ:peîVm b î ΊΗ'-Kîr« oï iiCl'l'k''' 'vauv J ! « \K Jîi ' t ί Min ' lfMv χ,ί * 1 , ' »' ^ M ' ï ' I ' > \iii i t -.-!-i-{ IM-«Kb. ;0-. ?-ρφ*nd»u0-.V'w*»l·?»'!4ÎM '1 ‘ beram* ;»'s«-4,4b p spe náiss küShx· boxsmkk (.*Μ * ' * ïinïeulkcu'bssnoikM?- aïe««-1 ï ! 'üKJreob S- jfMmi j-be?'!,·;λ>;;ï--Μ: - ρ 1per;<i in) - s -karboxan-kk <*H b<2>xdas3s<s35í!bksÍÍsá:í5Kb?|-2^(?-s]í?e5!Í-U|.;íj^a:í;ól^?-irí-í!«bi'-é'-ííih:öi'-e'·' kíxoxpm>-vxP"? <? ,VS <. V' «Ϊ WS (.‘Jï ; -S K V «i«J .Ç.-&amp;);« Hxïâ-î Iss * f' "^î^ïüê-i ^ liü" «5d;5Kbl''5~ltoeSs!i -S-exee! -( 4 -|ïiôd ist <4^^ 35-p3pi«T3^ 5 ί S- ΐ ; Vj br\2;-l!hh!'í:íi"2 os^spIr-^-l-SH-.S'.í •bs-ï!?v>s,iïiîï-4,-ï,-|«'ii1<’î'^H· l-kiiHX3Xii«ä'-'(-'-"i η».«:;· üb snbnrebx sü-!bj'bibin·ï- sbnenb' karba«««« j evi, -,exed' v X I Y ♦J «Γ i\* « b ' *!Γ,\Ι I * ' '*0* X * .febo>^!b [piperäÜ3)5*d e'i'd ? Hj-k-noha j- l -ksrhi'xsmid: **>.} -('-bicbb i Η- mà&amp;znl -Mlawid *-2- ! i -pqx'ndi«5lb2^s<^«M-''·^ΛΜκκ^«<"Λ^ lplpes'Khtt--4eb'b 1 Hbkmekej. s korboieüiid; 4 * > J "«ηνϋ\«ϊΚ<η * ! ' " e? ' ü t \ eo< ' elb^ ' .v.-i <'**««**'' ' Λνχ-ρνο 4,4bOÜ}-ki«<;li»v k^«tH>xesi'!id , ' t Λ' ' f' !l' ' t? « ' * ' 4\ V! X V ! ix \ '' 'v 1 «'s H Íií < I s ^ üMîU 2'i í,4|Í''!-*PC!^'!£'!' '' «b^'-'^o-ebSj-isved m*v-2 k«Ml· \% kx-tniua -φ»* 4.5 -* ^«karho'ofc** : H~ *«wrnl lU-m4mâ*% 8 men) ; -2b! -pir^w,wH-o«w*«il l-àôiKÈ: . > ;__M d-ten« i AMîkikijxpî«'«bb’'d4'.\ s ee S-kedv-eV-!.'·; í «un» «dk xK-«ï«<'iï '-i em'-;· : ! b-3f:ikv'i«i· > î!) ï&amp;sVS'i; MZ'Oxo-1 ebdíkiur?v2ü-k!&amp;5?ídsf!‘ X-!Í}-pírídíU5>· I kîï 11"-S-ïîm«Îïl>bâ-^ 4 ^ iüd" i ' ^ *vv îfkin ,v>in mIhimü ' sid'x, \'< pu^K^iUJ pipi'ex^^5" bk;nbo,\!b:;n ben:e> iec: « !. μ üï«,1„ V^n Ί,ι ' nptvb s w nî.ü, Js ?: P«H«'<í:í SÍ'' b-3-b bddj -I -«2 -Οχ*' í j-k dthubfi- J.Í b k-tiiS-iobn- ? - sI'? p-pej jdu«· i - kaibox ;be\ ; ; - > Hby><l3?.^j ? -(Nictsi)- b [4 bbejebbbu5.«bî'b>e!'aîi!·;-i '!lb2-<.-\o-'Îtstb-?sv;i?<b 3^^«^i-1ÍidadsK!öl;íSíi|^2^Pí(3''<3Kí5k|í.4^bi^p^í^fó8S-xöÍiiö'-3d!l|‘.ppen^j;^.iv^a^^{|i.:· amköj: -propK'3!ísv ci-felsiteil ^ser: : íá)^3 -p-ElôM1 P -bÄMP-SdJM - If4.-~p-ös.^ LMdsisld:m>MBMsís .k-<íIí-í5--3:--- I. ü):t Pipped pl'epMsePíV iív.íijl idei«; (*)^Pi:Osö^4:i4r<!üíjdf{Jí2B^kíms:R>HíV'3;#^pip]arkiö}·· í: - ^íí v|2-'| l:s4: |bí|>ípör S<1 b>S:3--iJt - -έΐ -1- (7-kK>;·'Ili· :S-slíPPísl}·>2'·^»^ΐέ1|·«ϊκί<!; í - í-3 í7 ?:îïî--! H· sedâSOS· 5 ϊλ)-3·>1;4 4.>.<íx;v i M ddnds<· ?ü k-s'usx.Msn- MdVpiperkljn- i ~ kärllöPd]-?usmh>> ·ρ·ρρκ4ίχ3Υ «ipái «ssían i .·. s -4-(l-Oxcr-; .4-4ihid*xí 2fl kíssaíí-Hr:- X·:O-pspeadui' i 4: es ixsx sK.s vi s-f1,4'ibspspcrsdsnn· r· 4 - ! ·· (7-aus· s í - iîsïi« ao J -:¾; -s ï-t &amp;íídi J-- 2 - <> ko> sí jl} ~ 3 í «id: : < ; > - :S - C ? - ^ ? ? - áSíds:í;ol'5 -4 3 ï > [ I ' 2 ' i 2'’ - <ssî<;>î;|:ï iro - í 4M - ' Ï ', ï - bösE:-í<sSÍ« :?i-5 - 4,.-4 ' pspcrs-iius!;'S:;^Ss:f suedi ésMPr; ^ :¾ > - 2 - ÇT - |s.'I iïti 1 -} ^ I--Lvíilsí s?:sí - S - il rs ><< 131| ~ 4 ϊ > κ ïs ·4 " ί' {2 ^ χο ' 1, >3 ílfx? -' 2 Η ^ saa:<ïiiS 4^3 ^ ? 1 ) -pijjiirl^lU's- ! -df vasea speál |s»ter; ét:}·:· ! -p .4''j8 íppeddlrú 8 Γ·ϋ·:'·:7·:'·η:;ϋ· ! 17 dpdspo 85 dime 81)-4 477*· -dshuBe· 8- ρχρρρΡ« · f4M -471-bemmxaximd.4xpáYnd;.sesj-hi.s8m' i ppms; IV.f.; f :S.#î!-Î3ïpiî>fêrî<i:iW:ïî>? i *^îïV v«s«çî>· i ,^^ÎfeÎ<î:^.-2H> kmsizplm-â4Î kpsperkto* i dlfdssfâm i. s4:4îîsî; {i. ; - ! H § ,4·4)4>χί^4'3.ia- vp4;4 4.4 jdix· 4'·;} ;-,?·{ 7--;nei::;· IB-beksse! · >· 4s?Ae«8-4· i 4· S 2-ox m ; :4 · ΐΙί&amp;Μΐ«χ2Μ^ ·8ΐ5Ρρ·4Ρ-'4ίΜχ ^}χΙϊΡ^Ρ}^^§^ΐΡ·§ρίΓ0[4.·41ίΐ^"Β"ΐΐ7'3Μ7"ΐ®.^Η^Ι.Β“ΐ^8®^ί^ΐ|ϊ^ΐ0^-ρ.\2’^8Μϊ<>-·2ί~ 8-Í>vSí4«x;sMp-4 >44pip8i-kN48]'S?up»·· I ppksp: Íé4>M>87f>imBi48(3pMp8|;84píteöl~34Im^ - dppspendi?':· 5 Hj bï.i::Γ<ίΓ;ίϊ<4:: C44eMiM^Bismf:ä8mm4P!ip448M'C7^asseP8lM':i5Ä^ èiuisxoHsvX'dPpipe-'sdin-d -áj · busán · ;.»-dsm·; C:*')-M7;':Msid-lM4miäKp8S'iImeki74-{44^ MsasMIm«^484kk4srj4p;4r4l}<-|N4|a-1 P-Pipsp s*s s-2·;?· Me-d-U8:edae:e8>·idead:)« ·πχΜ<4»ν···«·;Μ··8·-O-exe- i .4··αΜ;5ΐ;γ·3Η-χ·η;5χίΗ;η"8η5-psp<· sMssv 1: · s; |4η.>·έη· i pf-ΐΐίρρ 5 ύ 8.Y..3xDs;?seP8:88énvpp. ; Π··4ρ*κ4·>4η>ίηΐ84·οχο··44 ;\7 ·<!4ηάκ·4Γ··ΓίΚ<ϊΗρ;ρνΐ4!!·''.ΐ·· ΐ>ίίί · :í;í>:^í4Síí:í ~4 ,Ρ ’ > ^3 îpfeî'êiï ipiî jtÏCiï pitid ,ΐ (χ4·.?η T-Medl- ! M4sidï5:ep8 P s Ispsá!) - 1 -(pfpsddip I -48-M1. s,2 M ikids-p-2 -pxpxp ίκρ8ΐΡ -3 31 -bppxpxsxlnMM’^Jis^iálsifkdsiddp-l MîMîsxî; pipes sdm- ï ·ι88·ΐΐ;ΐη f A-<i<<>n: (3ï)-841 >4dB ipspedíBsí! 1'· Γ4Ρ V 4,{ PÍ2Psidsxs?lí S-llmpPI j)s#sf 133 4p||pd IP-3 VI !p?sss>x:ss;is-4.4Spqxtr;pinil;-b;pa::· i sb-dlnn. (-}· î 4.S .é-Diasa-B-aes-xpirp-i pUmaS-Pb 2-p H-mdssel· ëdnK-sdM-· p ::'..5n!Kh'i':-3:-es->sp;:x-' f4H'M74-:d4?íxssx4s3jS:M>43p^s5pd4s;lI4ppM«4.M-dl4P; ;>···! ·{ : i.4·Β$·.ν<;*·§···«>· .5Mgö'ij-0)-2-i i114¾¾¾-54)^01)-4-1442-ό:&amp;ο4 d-dOnOa-sH·- ï -' ä - ( jj M Ijids s<v§ ' 5-1 -'K <N îs^sïtl s '<4- <>?4 Í4 - (¾ ~í>js; οΊ ,4 - d 5¾ í4^-i-kips^slip -3-11 > - psp^riil«·:· ! ·:ί| · b-uiira sc-id ; >.;-5- 4Mf I ;-ki;?h;se;i}· 4-<>x o-1 ·;8-*.>~o<y>. 1.4-;:lih;<lro 4!\- km&amp;z-xh*· 3 dϊ pipertiiîsï" I >ïij' îâïïII} ? xKa2b8x!B8448re^8iji 5 -- s.11 - - ïsî>:>j5-- S' iîsîi' hxis 4>‘î5ïii 5< J:; «s gsüïsàk gÿôgy&amp;siK'^i'etiiiig dk%adhfc*6 x6j ês ^zolvâtjai. 34, ás I/i|é8:v]îmusKedmi v«gvt!©îv «tel R' R'A?^
    ΙΗΒΜοΙ-φί! IHáMsKoirSál ! 14-R4«s:oíRaM8s -s ! : ,4 'î>:R:dî<^' dïdC>5 2 i;:ï 5 ïî :Β4·Β*;η.-·:<·'ΐΚ;;<^·4·<·':?·6-0 id- D;lnd«v: 2;^;s/5iijïiKS3io;-8-öft-S 4
    I · Msäil·' t J - îpsîil :.s?o;-2 ·ο;:-6·; I
  5. 5- Jc'Etjl-IBicxsíSíícIí-S-ií:)·^· J114 - <2 -<ΐχ =;> - 4# ->ΐ4 i lis =âs4><- 2 Í44jsi £ïà:2o Μ:Ε5 - 3 J - j>íp«=rííi ίΡΐ-τ Sí ~5ïiss Jícs 52Í11 -äsSsbic?}-·ρ«=ρΙ<=;χ>·.;:Υ S i cïx' = 5=-p ipsXki 1::-4-41 cskick 4- -(4-^13^11--1:14-41^44341--:^^44414^52^3^3-1,4-ΒίΒίΒΐΧί-2 íí>Sfeiíísi^iSUts--2 -4I> ^:5'; 4c kís í'b<;;5tin:- Âîïsiïici ρίχίρΙΧϊΧχν I -ssxOl-xkä-kscxd ésKíss' 3 - (S7 --Míbí = 1H- kxbmsí-SS -4) -2 =-1 ;'4-{.;~C3=.>»1.4 -d k-xk- '- 2H-4; uxaxck-s - S3 4 is- piperx·«··· 5 -kpdxcs SS5| -m»4soj -pwpiösssas-1 .η ;·:ΐí í - =. í kí<.>?=t;> Ií éspiesç 3· Γ?··ϊ:^Ι· ΗΙ· Π ί .? · ·; ; 4 -{2 -<:»X'·· î .4 -<SïS;:;!r;'· «I i kl;>;:?Ou:v 1 · sU"|>;pcri;j;n· ; >i5i]j .'5ï:;tip}-f>K:pK:S>\;:Y 1 gpêÜl ·<: 3 NX' SÎI kiSSfe?: ixni«à}-papjöpsév 4- li-sll-ciy^hciil ésâlef; 3 >0?- IClös-- § I-ξ 05ïI-'S>10~X ' 11^-3S~îiÿ£î>-1 ridb:- i-kanxxsUp :-unirsi-íp-;-íri>pK:s«;*v 4 ävnis-vikkihv^il Pxssx:. 3 > ( '3' Bïi! -1H-s I- Ώ ΐ- s I î^32 -1 Í#“<2-ííxí5- î <îilïidm-3? ί3:%ϊΐΐίϊ^^Ι0^:3-0)-í>|í>ííxí0íí:í- k-kiii'böjüij ^ ::un!t:Oi -pri’pBnsav 4-|4nil.vikH>hcxn -.K««, '-Γ7 !v?<:îsl -1 B- 3-3)-2 - ί 0-:2-<ίΧ·'>-1 ^4 - -ΐ1ίΒΙ0ΐΐ î--333--klss<ï >î s ii -> 3 - - s3 ) ' jïip<fÎ'ss31 îî ' i -> kää i |- psássik -p:i\>pí:.>n.Nav 1 -besäBI-pspes-kliSä-B^Ü ésxtsaÿ 1M30MII-- ;î fî-^àâÂÇilf f iîtiÎiisô-3 ï-ï-liiïîiÎtiKfS Ιϊ?>::3-·ΐΐΐ'-:^ί^^ί<|£ΐ0 'i --.k-iî-iriwsi.ô.ll-·-· áíiilsöj -;p0plpís3íB I - |3B4il33--î|veôl éisâer; as 3-(?-Mei;i-! HysKla/.x!- νΠ;·2· ;ρΗ2·<>χο··Β·Ρ<;Ρ:χχ>ν B-k4ai::<!S<iki33· ilPppii^id:·;· I - kait-^tniâ--smisiï'k -prop;«ns3v k pinPx· 3 2 ekl éSsktiír ^^f'Sönak-'gyi>^«2^ss«tjfcf.'yiíg8átoKí-söi-v'*g^'k585Í>»iitó, 2.2. <jy<:gyN;'i:vcs3:3i ksxispnkdo. ax-ely skfedalaMa ás I--23, sgsnyp>«l:ö:k káPíBpke kkénöü á>ígVüBtpi 33, Λ,-: ; ·2'·: sgdrypGxxB Párss:u'íy!.kí.· íxíxmsi vygvÿB: kPx::-vx;IBsxs sriiurc-s kexelppy 3p. Λ:··: 1-22.. IgagyfpöÄ í>2?s-siciyiki: kpmp PgpIM ffelPssdPlksa :|vpgysaaPss3tl. kanpoBBp k<:-\;-:ïs-:-:.v:n:·, «íhcíy x-kgsc-s kczcBsBc v<:;s MippPipa,
HUE03736721A 2002-06-05 2003-05-27 Kalcitonin génnel kapcsolatos peptid receptor HUE032132T2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38613802P 2002-06-05 2002-06-05
US38861702P 2002-06-13 2002-06-13
US38987002P 2002-06-19 2002-06-19
US39320002P 2002-07-01 2002-07-01
US41353402P 2002-09-25 2002-09-25

Publications (1)

Publication Number Publication Date
HUE032132T2 true HUE032132T2 (hu) 2017-09-28

Family

ID=29741144

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE03736721A HUE032132T2 (hu) 2002-06-05 2003-05-27 Kalcitonin génnel kapcsolatos peptid receptor

Country Status (24)

Country Link
US (2) US20040063735A1 (hu)
EP (1) EP1539766B1 (hu)
JP (1) JP4490809B2 (hu)
KR (2) KR20050008790A (hu)
CN (1) CN100558728C (hu)
AU (1) AU2003237255B8 (hu)
BR (1) BRPI0311812B8 (hu)
CA (1) CA2487976C (hu)
CY (1) CY1118764T1 (hu)
DK (1) DK1539766T3 (hu)
ES (1) ES2616539T3 (hu)
GE (1) GEP20074231B (hu)
HR (1) HRP20041147A2 (hu)
HU (1) HUE032132T2 (hu)
IS (1) IS7583A (hu)
LT (1) LT1539766T (hu)
MX (1) MXPA04011960A (hu)
NO (1) NO332691B1 (hu)
NZ (1) NZ537315A (hu)
PL (1) PL374017A1 (hu)
PT (1) PT1539766T (hu)
RS (1) RS52552B (hu)
TW (1) TWI308151B (hu)
WO (1) WO2003104236A1 (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1685102A4 (en) * 2003-11-12 2008-08-20 Lg Life Sciences Ltd melanocortin
CA2549330A1 (en) * 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
AR046787A1 (es) * 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
JP4769082B2 (ja) * 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
WO2005084672A1 (de) * 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
GEP20084420B (en) 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7547694B2 (en) * 2004-04-15 2009-06-16 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7696192B2 (en) * 2004-09-09 2010-04-13 Merck Sharp & Dohme Corp. Tricyclic anilide spirolactam CGRP receptor antagonists
CA2580020A1 (en) * 2004-09-09 2006-03-23 Ian M. Bell Aryl spirolactam cgrp receptor antagonists
US7750010B2 (en) * 2004-09-13 2010-07-06 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantion CGRP receptor antagonists
US7659264B2 (en) * 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
BRPI0517418A (pt) * 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
CN101039718A (zh) * 2004-10-14 2007-09-19 默克公司 Cgrp受体拮抗剂
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
WO2007034326A2 (en) 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP3842458A1 (en) 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
MX2008015906A (es) * 2006-06-13 2009-03-06 Vertex Pharma Antagonistas del receptor del peptido relacionado con el gen de calcitonina.
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
CN101553231A (zh) * 2006-08-15 2009-10-07 弗特克斯药品有限公司 毒蕈碱受体调节剂
US8067447B2 (en) * 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CA2673108A1 (en) 2006-12-08 2008-06-19 Merck & Co., Inc. Constrained spirocyclic compounds as cgrp receptor antagonists
US8026365B2 (en) 2007-05-25 2011-09-27 Hoffman-La Roche Inc. 4,4-disubstituted piperidine derivatives
AU2008313733A1 (en) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh CGRP antagonists
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
US8481546B2 (en) 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
CA2836649C (en) 2011-05-20 2020-06-23 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
EP2709663B1 (en) 2011-05-20 2019-03-20 AlderBio Holdings LLC Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20200126018A (ko) 2014-03-21 2020-11-05 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
WO2019112024A1 (ja) * 2017-12-08 2019-06-13 キッセイ薬品工業株式会社 ピロリジン化合物
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
MX2021012354A (es) 2019-04-11 2021-10-22 Scherer Technologies Llc R P Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
CN117624191A (zh) * 2022-08-30 2024-03-01 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
AU3993795A (en) * 1994-12-02 1996-06-19 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for prevention and/or treatment of no-mediated diseases
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
US5869489A (en) * 1996-03-25 1999-02-09 Merck & Co., Inc. Trypthophan ureas as neurokinnin antagonists
WO1997042951A1 (en) * 1996-05-16 1997-11-20 Board Of Regents, The University Of Texas System Methods of identifying modulators of perivascular sensory nerve ca2+ receptors
CA2264942A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
EA004037B1 (ru) * 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6063796A (en) * 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) * 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
AU5265599A (en) 1998-04-08 1999-11-01 Takeda Chemical Industries Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
EP1117662A1 (en) 1998-09-30 2001-07-25 Merck Sharp &amp; Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19963868A1 (de) * 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR20030036724A (ko) * 2000-09-14 2003-05-09 도레이 가부시끼가이샤 우레아 유도체 및 그것을 유효성분으로 하는 접착분자저해제
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040248816A1 (en) * 2003-04-01 2004-12-09 Boehringer Ingelheim International Gmbh Treatment of migraine
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US20050032783A1 (en) * 2003-07-07 2005-02-10 Boehringer Ingelheim International Gmbh Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
AR046787A1 (es) * 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
WO2005084672A1 (de) * 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004018796A1 (de) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
US7696195B2 (en) * 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004027912A1 (de) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof

Also Published As

Publication number Publication date
CY1118764T1 (el) 2017-07-12
JP2005538959A (ja) 2005-12-22
CA2487976A1 (en) 2003-12-18
KR20050008790A (ko) 2005-01-21
AU2003237255B8 (en) 2010-01-07
IS7583A (is) 2004-12-03
PT1539766T (pt) 2017-03-02
DK1539766T3 (en) 2017-04-03
TWI308151B (en) 2009-04-01
LT1539766T (lt) 2017-03-10
BRPI0311812B8 (pt) 2021-05-25
TW200407327A (en) 2004-05-16
RS104004A (en) 2006-10-27
AU2003237255B2 (en) 2009-12-17
NO332691B1 (no) 2012-12-10
NZ537315A (en) 2006-04-28
CN1671711A (zh) 2005-09-21
ES2616539T3 (es) 2017-06-13
WO2003104236A1 (en) 2003-12-18
JP4490809B2 (ja) 2010-06-30
EP1539766B1 (en) 2016-12-21
CA2487976C (en) 2011-07-26
US20040063735A1 (en) 2004-04-01
US20070148093A1 (en) 2007-06-28
MXPA04011960A (es) 2005-03-31
PL374017A1 (en) 2005-09-19
BRPI0311812B1 (pt) 2016-04-19
RS52552B (en) 2013-04-30
KR20120004541A (ko) 2012-01-12
BR0311812A (pt) 2005-03-29
EP1539766A1 (en) 2005-06-15
NO20045219L (no) 2005-02-28
HRP20041147A2 (en) 2005-08-31
AU2003237255A1 (en) 2003-12-22
EP1539766A4 (en) 2007-08-08
GEP20074231B (en) 2007-11-12
CN100558728C (zh) 2009-11-11

Similar Documents

Publication Publication Date Title
HUE032132T2 (hu) Kalcitonin génnel kapcsolatos peptid receptor
US7754732B2 (en) Spirocyclic anti-migraine compounds
US7772244B2 (en) Therapeutic agents for the treatment of migraine
US7842808B2 (en) Anti-migraine spirocycles
WO2005065779A1 (en) Calcitonin gene related peptide receptor antagonists
IL165445A (en) Heterocyclic compounds and pharmaceutical compositions containing the same
MXPA06006070A (en) Calcitonin gene related peptide receptor antagonists
ZA200604503B (en) Calcitonin gene related peptide receptor antagonists
MXPA06011025A (es) Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) heterociclicos para el tratamiento de la migraña
UA80977C2 (en) Calcitonin gene related peptide receptor antagonists, pharmaceutical composition based thereon, method for treatment of migraine
KR20060125832A (ko) 칼시토닌 유전자 관련 펩티드 수용체 길항제